Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-5 of 5

Sort by

Sort Order Select

Journal Articles

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

Shem Patyna, A. Douglas Laird, Dirk B. Mendel, Anne-Marie O'Farrell, Chris Liang, Huiping Guan, Tomas Vojkovsky, Stefan Vasile, Xueyan Wang, Jeffrey Chen, Maren Grazzini, Cheng Y. Yang, Joshua Ö. Haznedar, Juthamas Sukbuntherng, Wei-Zhu Zhong, Julie M. Cherrington, Dana Hu-Lowe

Mol Cancer Ther (2006) 5 (7): 1774–1782.

https://doi.org/10.1158/1535-7163.MCT-05-0333

Published: 04 August 2006

View article titled, SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

Journal Articles

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Olga Potapova, A. Douglas Laird, Michelle A. Nannini, Angela Barone, Guangmin Li, Katherine G. Moss, Julie M. Cherrington, Dirk B. Mendel

Mol Cancer Ther (2006) 5 (5): 1280–1289.

https://doi.org/10.1158/1535-7163.MCT-03-0156

Published: 26 May 2006

View article titled, Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Journal Articles

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

Tinya J. Abrams, Lesley J. Murray, Enrico Pesenti, Vicky Walker Holway, Tina Colombo, Leslie B. Lee, Julie M. Cherrington, Nancy K. Pryer

Mol Cancer Ther (2003) 2 (10): 1011–1021.

Published: 24 October 2003

View article titled, Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

Journal Articles

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer

Tinya J. Abrams, Leslie B. Lee, Lesley J. Murray, Nancy K. Pryer, Julie M. Cherrington

Mol Cancer Ther (2003) 2 (5): 471–478.

Published: 01 May 2003

View article titled, SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer

Journal Articles

Src Family Kinase Activity Is Required for Signal Tranducer and Activator of Transcription 3 and Focal Adhesion Kinase Phosphorylation and Vascular Endothelial Growth Factor Signaling in Vivo and for Anchorage-dependent and -independent Growth of Human Tumor Cells

A. Douglas Laird, Guangmin Li, Katherine G. Moss, Robert A. Blake, Martin A. Broome, Julie M. Cherrington, Dirk B. Mendel

Mol Cancer Ther (2003) 2 (5): 461–469.

Published: 01 May 2003

View article titled, Src Family Kinase Activity Is Required for Signal Tranducer and Activator of Transcription 3 and Focal Adhesion Kinase Phosphorylation and Vascular Endothelial Growth Factor Signaling <em>in Vivo</em> and for Anchorage-dependent and -independent Growth of Human Tumor Cells

NARROW

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer

Src Family Kinase Activity Is Required for Signal Tranducer and Activator of Transcription 3 and Focal Adhesion Kinase Phosphorylation and Vascular Endothelial Growth Factor Signaling in Vivo and for Anchorage-dependent and -independent Growth of Human Tumor Cells

Email alerts

AACR Journals

SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity

Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248

Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with “standard of care” therapeutic agents for the treatment of breast cancer

SU11248 Inhibits KIT and Platelet-derived Growth Factor Receptor β in Preclinical Models of Human Small Cell Lung Cancer

Src Family Kinase Activity Is Required for Signal Tranducer and Activator of Transcription 3 and Focal Adhesion Kinase Phosphorylation and Vascular Endothelial Growth Factor Signaling in Vivo and for Anchorage-dependent and -independent Growth of Human Tumor Cells

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only